About Lycia Therapeutics
Building the leading extracellular protein degradation company
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Founded
- 2020
- Company type
- Privately Held
At Lycia, we aim to eliminate the source of disease using the power of extracellular protein degradation. Our novel LYTAC therapeutics are designed to bind and remove disease-causing extracellular proteins by directing them into the cell for degradation via the lysosome. Focused initially on autoimmune and inflammatory diseases, our platform addresses gaps in targeting proteins outside the cell, offering new hope to patients who urgently need better options.
Company locations
E Jamie Ct, South San Francisco, California 94080, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 6,346
- People linked to this company
- 38
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.